Alcohol and Cocaine Use and Abuse Among Opioid Addicts Engaged in a Methadone Maintenance Treatment Program, I Maremmani, MD, P P Pani, MD. A Mellini, MD , M Pacini, MD, G Marini, M Lovrecic, MD, G Pertugi, MD and M Shinderman, MD J Addict Dis. 2007;26(1):61-70.
Cytochrome P4503A4 Metabolic Activity, Methadone Blood Concentrations, and Methadone Doses, Shinderman, M, Maxwell, S, Brawand-Amey, M, Golay KP, Baumann P, Eap CB, Drug Alcohol Depend, 2003, Mar, 1:69(2).205-11
When “Enough” Is Not Enough: New Perspectives on Optimal Methadone Maintenance Dose, Leavitt, S, Shinderman, M, et al, Mt Sin J Med Vol 67 N. 5 & 6, Oct/Nov 2000 (PDF format may require Acrobat Reader.)
Optimizing Response to Methadone Maintenance Treatment Higher-Dose Methadone, Maxwell,S., Shinderman, M. (Abstract Only) For full text, contact: J Psychoactive Drugs, Vol Apr-Jun, 1999
The “Dear Doctor” Letter, Dr. Shinderman’s (CAP’s) letter for use by his MMT patients to educate their physicians regarding the treatment of pain, drug interactions, anti-viral therapy and organ transplants as they are related to methadone maintenance. MMT practitioners are encouraged to adapt CAP’s letter to their needs.
Methadone Dose and Retention During Treatment of Heroin Addicts with Axis I Psychiatric Co- morbidity, Icro Maremmani, MD, Orietta Zolesi, MD, Mirella Aglietti, MD, Giada Marini, MD, Alessandro Tagliamonte, MD, Marc Shinderman, MD, Sarz Maxwell, MD., J Add Dis Vol 19, No 2, 2000
Chronic Use Of Opioids and Antipsychotic Drugs: Side Effects, Effects On Endogenous Opioids, and Toxicity, Mary Jeanne Kreek and Neil Hartmann, Annals New York Academy of Sciences pp151-172, Rockefeller University, NYC, New York 10021